Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 5/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 2/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 2/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.67 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.67 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4176661 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL8049183 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL16431424 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL23992003 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL12171707 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL23668326 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL8388177 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL8048373 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL2502820 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL8384466 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260042933-A1 | Formulation For Simultaneous Rejuvenation And Protection Of The Interior Fibers And Exterior Surfaces Of Wood | WINGET RICHARD (US) | 2026-02-12 | — | — | US | claimed |
| CN-117717157-B | Preparation method of transparent emulsified nano essence with low surfactant | 嘉兴未来食品研究院 | 2025-05-09 | — | — | CN | claimed |
| WO-2024254056-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | CATALENT ONTARIO LIMITED (CA) | 2024-12-12 | — | — | WO | claimed |
| US-11793754-B1 | Sodium hypochlorite and chlorhexidine based nanoemulsions and a method of preparation thereof | KING ABDULAZIZ UNIVERSITY (SA) | 2023-10-24 | — | — | US | claimed |
| CN-116370345-A | Transparent oil solution containing ceramide and sphingosine and preparation method thereof | 重庆智合生物医药有限公司 | 2023-07-04 | — | — | CN | claimed |
| CN-116139082-A | Self-microemulsion composition and preparation and application thereof | 湖南慧泽生物医药科技有限公司 | 2023-05-23 | — | — | CN | claimed |
| EP-2525827-B1 | PHARMACEUTICAL FORMULATIONS OF LORATADINE FOR ENCAPSULATION AND COMBINATIONS THEREOF | CATALENT ONTARIO LTD (CA) | 2020-11-18 | — | — | EP | claimed |
| EP-3653204-A1 | PHARMACEUTICAL FORMULATIONS OF LORATADINE FOR ENCAPSULATION AND COMBINATIONS THEREOF | Catalent Ontario Limited (CA) | 2020-05-20 | — | — | EP | claimed |
| WO-2013008083-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFICACY OF TAMOXIFEN | NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (NIPER) (IN) | 2013-01-17 | — | — | WO | claimed |
| US-20120301544-A1 | PHARMACEUTICAL FORMULATIONS OF LORATADINE FOR ENCAPSULATION AND COMBINATIONS THEREOF | ACCUCAPS INDUSTRIES LIMITED (CA) | 2012-11-29 | — | — | US | claimed |
| WO-2011088550-A1 | PHARMACEUTICAL FORMULATIONS OF LORATADINE FOR ENCAPSULATION AND COMBINATIONS THEREOF | ACCUCAPS INDUSTRIES LIMITED (CA) | 2011-07-28 | — | — | WO | claimed |
| WO-2011004395-A1 | MICROEMULSION FORMULATION FOR BIOLOGICALS | INTAS BIOPHARMACEUTICALS LIMITED (IN) | 2011-01-13 | — | — | WO | claimed |
| EP-0995430-A2 | Use of diacylolycerols for enhancing the barrier function of the skin | Beiersdorf Aktiengesellschaft (DE) | 2000-04-26 | — | — | EP | claimed |
| EP-0655907-B1 | USE OF DIACYLOLYCEROLS FOR INCREASING THE MELANIN CONTENT IN MELANOCYTES | UNIV BOSTON (US) | 1999-04-28 | — | — | EP | claimed |
| EP-0542108-B1 | Stabilizers for plastic materials | CIBA GEIGY AG (CH) | 1997-09-24 | — | — | EP | claimed |
| EP-0730001-A1 | Stabilizers for plastic materials | F. HOFFMANN-LA ROCHE AG (CH) | 1996-09-04 | — | — | EP | claimed |
| WO-1996009810-A1 | METHODS FOR ENHANCING MELANIN SYNTHESIS IN MELANOCYTES USING DIACYLGLYCEROLS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 1996-04-04 | — | — | WO | claimed |
| EP-0542108-A2 | Stabilizers for plastic materials | F. HOFFMANN-LA ROCHE AG (CH) | 1993-05-19 | — | — | EP | claimed |
| JP-8245830-A | — | — | None | — | — | JP | disclosed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | disclosed |
| US-20260042933-A1 | Formulation For Simultaneous Rejuvenation And Protection Of The Interior Fibers And Exterior Surfaces Of Wood | WINGET RICHARD (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250213497-A1 | A NANO IN MICRO FORMULATION AND PROCESS THEREOF | AMRITA VISHWA VIDYAPEETHAM (IN) | 2025-07-03 | — | — | US | disclosed |
| EP-3728487-B1 | METHOD OF REMOVING POLYMERIC MATERIAL COMPRISING HETEROATOMS FROM A SURFACE USING COMPOSITIONS INCLUDING A KETO-ESTER COMPOUND | FOURTH PRINCIPLE LLC (US) | 2025-07-02 | — | — | EP | disclosed |
| CN-119264010-A | Meta-diacyl compound and application thereof | 河南蓝创作物科学有限公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-2024254056-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | CATALENT ONTARIO LIMITED (CA) | 2024-12-12 | — | — | WO | disclosed |
| CN-116514743-B | Paclitaxel-fatty acid prodrug, self-microemulsion preparation, and preparation methods and applications thereof | 沈阳药科大学 | 2024-11-29 | — | — | CN | disclosed |
| CN-118304270-A | Vitamin D drop and preparation method thereof | 青岛双鲸药业股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118078759-A | Cefditoren pivoxil granule pharmaceutical composition and preparation method thereof | 凌晟(武汉)生物医药技术有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11969496-B2 | Non-greasy personal care compositions | COLGATE-PALMOLIVE COMPANY (US) | 2024-04-30 | — | — | US | disclosed |
| CN-117297174-A | Filter stick capable of automatically changing taste and preparation method thereof | 四川三联新材料有限公司 | 2023-12-29 | — | — | CN | disclosed |
| US-11793754-B1 | Sodium hypochlorite and chlorhexidine based nanoemulsions and a method of preparation thereof | KING ABDULAZIZ UNIVERSITY (SA) | 2023-10-24 | — | — | US | disclosed |
| CN-116898831-A | External agent composition containing S-flurbiprofen | 江苏恒瑞医药股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023187831-A1 | A NANO IN MICRO FORMULATION AND PROCESS THEREOF | AMRITA VISHWA VIDYAPEETHAM (IN) | 2023-10-05 | — | — | WO | disclosed |
| CN-116514743-A | Paclitaxel-fatty acid prodrug, self-microemulsion preparation, and preparation methods and applications thereof | 沈阳药科大学 | 2023-08-01 | — | — | CN | disclosed |
| US-20220362135-A1 | Non-Greasy Personal Care Compositions | COLGATE-PALMOLIVE COMPANY (US) | 2022-11-17 | — | — | US | disclosed |
| US-11433018-B2 | Non-greasy personal care compositions | COLGATE-PALMOLIVE COMPANY (US) | 2022-09-06 | — | — | US | disclosed |
| US-11370996-B2 | Compositions including keto-ester compounds and methods of using the same | FOURTH PRINCIPLE, LLC (US) | 2022-06-28 | — | — | US | disclosed |
| CN-114591232-A | Long-acting control agent for ectoparasites of animals | 三井化学AGRO株式会社 | 2022-06-07 | — | — | CN | disclosed |
| CN-111132549-B | Long-acting control agent for ectoparasites of animals | 三井化学AGRO株式会社 | 2022-04-12 | — | — | CN | disclosed |
| EP-3179979-B1 | NON-GREASY PERSONAL CARE COMPOSITIONS | COLGATE PALMOLIVE CO (US) | 2021-04-21 | — | — | EP | disclosed |
| US-20200377823-A1 | COMPOSITIONS INCLUDING KETO-ESTER COMPOUNDS AND METHODS OF USING THE SAME | TALK ABOUT IT SOLUTIONS | 2020-12-03 | — | — | US | disclosed |
| EP-2525827-B1 | PHARMACEUTICAL FORMULATIONS OF LORATADINE FOR ENCAPSULATION AND COMBINATIONS THEREOF | CATALENT ONTARIO LTD (CA) | 2020-11-18 | — | — | EP | disclosed |
| EP-3728487-A2 | COMPOSITIONS INCLUDING KETO-ESTER COMPOUNDS AND METHODS OF USING THE SAME | Fourth Principle, LLC. (US) | 2020-10-28 | — | — | EP | disclosed |
| WO-2020142273-A1 | COMPOSITIONS AND METHODS FOR REMOVING COATINGS FROM SURFACES | FOURTH PRINCIPLE, LLC (US) | 2020-07-09 | — | — | WO | disclosed |
| EP-3653204-A1 | PHARMACEUTICAL FORMULATIONS OF LORATADINE FOR ENCAPSULATION AND COMBINATIONS THEREOF | Catalent Ontario Limited (CA) | 2020-05-20 | — | — | EP | disclosed |
| CN-111132549-A | Long-acting control agent for ectoparasites of animals | 三井化学AGRO株式会社 | 2020-05-08 | — | — | CN | disclosed |
| US-20200030223-A1 | Non-Greasy Personal Care Compositions | COLGATE-PALMOLIVE COMPANY (US) | 2020-01-30 | — | — | US | disclosed |
| US-20190350821-A1 | SURFACTANT-FREE EMULSION COMPOSITION | GREENVINES BIOTECH CO., LTD. (TW) | 2019-11-21 | — | — | US | disclosed |
| US-10470999-B2 | Non-greasy personal care compositions | COLGATE-PALMOLIVE COMPANY (US) | 2019-11-12 | — | — | US | disclosed |
| US-10470998-B2 | Non-greasy personal care compositions | COLGATE-PALMOLIVE COMPANY (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3185845-B1 | NON-GREASY PERSONAL CARE COMPOSITIONS | COLGATE PALMOLIVE CO (US) | 2019-03-27 | — | — | EP | disclosed |
| US-20170326092-A1 | ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-11-16 | — | — | US | disclosed |
| US-20170252288-A1 | Non-Greasy Personal Care Compositions | COLGATE-PALMOLIVE COMPANY (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170246104-A1 | Non-Greasy Personal Care Compositions | COLGATE-PALMOLIVE COMPANY (US) | 2017-08-31 | — | — | US | disclosed |
| EP-3185845-A1 | NON-GREASY PERSONAL CARE COMPOSITIONS | Colgate-Palmolive Company (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-3179979-A1 | NON-GREASY PERSONAL CARE COMPOSITIONS | Colgate-Palmolive Company (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-3148645-A1 | ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN | Sun Pharmaceutical Industries Ltd (IN) | 2017-04-05 | — | — | EP | disclosed |
| WO-2016048425-A1 | NON-GREASY PERSONAL CARE COMPOSITIONS | COLGATE-PALMOLIVE COMPANY (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016048274-A1 | NON-GREASY PERSONAL CARE COMPOSITIONS | COLGATE-PALMOLIVE COMPANY (US) | 2016-03-31 | — | — | WO | disclosed |
| US-20160081965-A1 | ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-03-24 | — | — | US | disclosed |
| WO-2015186039-A1 | ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2015-12-10 | — | — | WO | disclosed |
| EP-2877178-A1 | PHARMACEUTICAL COMPOSITION COMPRISING DIAMORPHINE FOR INTRANASAL ADMINISTRATION | Wockhardt Limited (IN) | 2015-06-03 | — | — | EP | disclosed |
| WO-2015059466-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING EFAVIRENZ | CIPLA LIMITED (IN) | 2015-04-30 | — | — | WO | disclosed |
| WO-2014016653-A1 | PHARMACEUTICAL COMPOSITION COMPRISING DIAMORPHINE FOR INTRANASAL ADMINISTRATION | WOCKHARDT LIMITED (IN) | 2014-01-30 | — | — | WO | disclosed |
| WO-2013088274-A1 | ANHYDROUS AMORPHOUS AZITHROMYCIN COMPOSITION FREE OF AZITHROMYCIN DIHYDRATE | WOCKHARDT LIMITED (IN) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013008083-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFICACY OF TAMOXIFEN | NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (NIPER) (IN) | 2013-01-17 | — | — | WO | disclosed |
| EP-2544887-A1 | A DEVICE FOR THE MANUFACTURE OF A DOSAGE FORM WITH A HOLE AND METHOD OF MANUFACTURE | Wockhardt Limited (IN) | 2013-01-16 | — | — | EP | disclosed |
| EP-2542243-A2 | MODIFIED RELEASE DOSAGE FORM | Wockhardt Limited (IN) | 2013-01-09 | — | — | EP | disclosed |
| US-20120301544-A1 | PHARMACEUTICAL FORMULATIONS OF LORATADINE FOR ENCAPSULATION AND COMBINATIONS THEREOF | ACCUCAPS INDUSTRIES LIMITED (CA) | 2012-11-29 | — | — | US | disclosed |
| EP-2521537-A2 | PHARMACEUTICAL COMPOSITION FOR MODIFIED DELIVERY OF ACTIVES | Wockhardt Limited (IN) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011110989-A1 | A DEVICE FOR THE MANUFACTURE OF A DOSAGE FORM WITH A HOLE AND METHOD OF MANUFACTURE | WOCKHARDT LIMITED (IN) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011107944-A2 | MODIFIED RELEASE DOSAGE FORM | WOCKHARDT LIMITED (IN) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011088550-A1 | PHARMACEUTICAL FORMULATIONS OF LORATADINE FOR ENCAPSULATION AND COMBINATIONS THEREOF | ACCUCAPS INDUSTRIES LIMITED (CA) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011080716-A2 | PHARMACEUTICAL COMPOSITION FOR MODIFIED DELIVERY OF ACTIVES | WOCKHARDT LIMITED (IN) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011004395-A1 | MICROEMULSION FORMULATION FOR BIOLOGICALS | INTAS BIOPHARMACEUTICALS LIMITED (IN) | 2011-01-13 | — | — | WO | disclosed |
| US-20080118490-A1 | Combined use of triglycerides containing medium chain fatty acids and exogenous lipolytic enzymes as feed supplements | VITAMEX,N.V. (BE) | 2008-05-22 | — | — | US | disclosed |
| EP-0995430-A2 | Use of diacylolycerols for enhancing the barrier function of the skin | Beiersdorf Aktiengesellschaft (DE) | 2000-04-26 | — | — | EP | disclosed |
| EP-0655907-B1 | USE OF DIACYLOLYCEROLS FOR INCREASING THE MELANIN CONTENT IN MELANOCYTES | UNIV BOSTON (US) | 1999-04-28 | — | — | EP | disclosed |
| US-5750091-A | Methods for increasing melanin content in melanocytes using diacylglycerols and uses thereof | THE TRUSTEES OF BOSTON UNIVERSITY (US) | 1998-05-12 | — | — | US | disclosed |
| US-5700450-A | Methods for enhancing melanin synthesis in melanocytes using diacyglycerols and uses thereof | THE TRUSTEES OF BOSTON UNIVERSITY (US) | 1997-12-23 | — | — | US | disclosed |
| EP-0542108-B1 | Stabilizers for plastic materials | CIBA GEIGY AG (CH) | 1997-09-24 | — | — | EP | disclosed |
| JP-H08245830-A | STABILIZER FOR PLASTIC MATERIAL | F HOFFMANN LA ROCHE AG | 1996-09-24 | — | — | JP | disclosed |
| EP-0730001-A1 | Stabilizers for plastic materials | F. HOFFMANN-LA ROCHE AG (CH) | 1996-09-04 | — | — | EP | disclosed |
| US-5352440-A | Methods for increasing melanin content in melanocytes using diacylglycerols and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 1994-10-04 | — | — | US | disclosed |
| US-5308549-A | OF ALPHA-TOCOPHEROL, GLYCERIN, POLYOXYETHYLENE GLYCOL AND GLYCERYL MONOCAPRYLATE-CAPRATE | HOFFMANN-LA ROCHE INC. (US) | 1994-05-03 | — | — | US | disclosed |
| EP-0566718-A1 | STABILIZERS FOR PLASTIC MATERIALS | Ciba SC Holding AG (CH) | 1993-10-27 | — | — | EP | disclosed |
| WO-1993010175-A1 | STABILIZERS FOR PLASTIC MATERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 1993-05-27 | — | — | WO | disclosed |
| EP-0542108-A2 | Stabilizers for plastic materials | F. HOFFMANN-LA ROCHE AG (CH) | 1993-05-19 | — | — | EP | disclosed |
| EP-0542108-A2 | Stabilizers for plastic materials | F. HOFFMANN-LA ROCHE AG (CH) | 1993-05-19 | — | — | EP | disclosed |
| EP-0542108-A2 | Stabilizers for plastic materials | F. HOFFMANN-LA ROCHE AG (CH) | 1993-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042933-A1 | Formulation For Simultaneous Rejuvenation And Protection Of The Interior Fibers And Exterior Surfaces Of Wood | PPARA, ELOVL1, ELOVL3 | PRKCA 2717/4885PRKCE 1880/4885PRKCQ 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.